According to the petition Courtney Anguiano knowingly conspired with seven other people to submit 189 false and fraudulent post-transaction reimbursement requests under three different Eli Lilly and Co. savings card programs.
Top executives and directors of Indianapolis-based Point Biopharma Global Inc. could rake in an eye-popping $212 million from their deal to sell the company to drugmaker Eli Lilly and Co.
The results, which were also presented Sunday at a medical conference, confirm that the drug made by Eli Lilly and Co. has the potential to be one of the most powerful medical treatments for obesity to date, outside experts said.
Representatives from the state’s colleges and universities conceded that rising tuition costs are deterring thousands of students from post-high school educations.
During a forum Thursday hosted by the not-for-profit Indiana Fiscal Policy Institute, officials from IU and Purdue emphasized continuing opportunities for collaboration even as both schools create two independent urban campuses in Indianapolis.
He might just be the locksmith they need to completely take over the economic hub of Indiana, forcing more Hoosiers and businesses to consider moving elsewhere.
Since July 2022, the city has annexed a total of about 7,840 acres for the LEAP Lebanon Innovation and Research District, a planned technology and advanced manufacturing hub.
As Indiana competes with neighboring states for computer-chip and electric-vehicle production plants, some state leaders remain concerned that Hoosiers are ill-equipped to fill the jobs of the future should those corporations decide to locate here.
State-by-state comparisons from the Kauffman Foundation, the nation’s leading institution focused on encouraging entrepreneurship, consistently rank Indiana in the bottom half of all states.
Eli Lilly and Co. is paying Indianapolis-based startup Point Biopharma $12.50 a share, an 85% premium over the company’s closing price on Monday of $6.68 a share.
Eli Lilly and Co. just hit another bump in the road in its quest to push deeper into treatments for skin diseases, the third setback this year for the Indianapolis-based drugmaker from the U.S Food and Drug Administration.
Two state lawmakers are drafting legislation that would create a permitting process and require a deeper public review of any effort in the state to pump 10 million gallons or more per day from a community’s aquifer. Meanwhile, the West Lafayette City Council is poised to consider a resolution Monday night opposing the IEDC’s plans.
The decision represents a rare case of a judge overturning a jury verdict and is a major win for Lilly, which argued strenuously that its Emgality drug is substantially different than Anjovy, a drug sold by competitor Teva Pharmaceuticals.
Paul Halverson, the founding dean of the Indiana University Fairbanks School of Public Health, is a longtime advocate for a stronger role for public health across the state.
